National Health Underwriters
Medicaid Expansion: Who Qualifies at 138 Percent of the Poverty Line — and Who Falls in the Gap
Read moreFDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs
Read more
Supplements That Actually Work, According to Science
A short, evidence-first list for readers tired of shelf clutter — and honest notes on what the science does not support.
Supplements
Supplements for Weight Loss: Sorting Hype From Help
Most fat-burning pills rest on thin evidence. A few ingredients have modest data — and none of them replace the fundamentals.
Supplements
What a Workplace Health Fair Can Do for You: Lessons From One Missouri Employer
Missouri Military Academy turned one August day into screenings, benefit answers and simple habits. Here's how to get the same value from any employer event.
Supplements
Melatonin for Sleep: What the Evidence Supports and What Gummies Overshoot
Melatonin helps with circadian timing problems, not general insomnia — and analyses keep finding gummies with far more hormone than the label claims.
Supplements
Do Multivitamins Work? What the USPSTF and Large Cohorts Concluded
For preventing heart disease, cancer or death in healthy adults, the evidence favors food — with narrower benefits in specific groups.
Insurance
See all →
What the HealthPartners-Essentia Merger Means for Midwest Patients and Members
Two Minnesota nonprofit giants plan a 22-hospital combination by Jan. 1, 2027 — and 1.6 million health plan members are watching what changes.
Deductibles Explained: Why You Pay Before Insurance Kicks In
The deductible is the number that decides how much of a bad year you pay for yourself.
Underwriting After the ACA: What Health Insurers Can and Cannot Price On
Guaranteed issue ended medical rejection for ACA-compliant plans, but rating still moves on age, geography, tobacco and plan type — and outside the ACA, old rules persist.
Research
Peer Review Explained: Who Checks the Science?
Before a study reaches a journal, a handful of unpaid experts read it closely. Here is what they can catch, and what they cannot.
Surrogate Endpoints: When a Trial Measures a Stand-In Instead of the Outcome You Care About
Trials often track cholesterol, tumor shrinkage or blood sugar instead of death, fractures or survival — the stand-in usually works, but history records the exceptions.
“50% Higher Risk”: Relative vs Absolute Risk in Health News
Relative risk makes small dangers look enormous and big benefits look magical; converting to absolute numbers takes one minute and changes every conclusion.
Coverage
Medicare Coverage Gaps and How to Fill Them
Original Medicare covers about half of a beneficiary's health costs. Here is what it leaves out, and the three routes people use to close the holes.
UnitedHealth Raised Its 2026 Forecast as Cost Ratio Cooled to 86.7 Percent
The July 16, 2026 quarter showed the 2025 cost surge has crested, with guidance lifted to $19.50-$20.00 adjusted EPS. What margin recovery means for members.
AHIP and Blue Cross Blue Shield Pledged New Prior Authorization Reforms
Late-June 2026 commitments from the two biggest insurer trade groups target shrinking prior auth lists and honoring approvals across plan switches.
Health News
Same Weight Loss, Different Health Gains: What the Keto Trial Found
Three diets each cut about 10% of body weight. Only one produced the biggest liver and blood sugar improvements.
Vaccine News Explained: How to Read Safety and Efficacy Reporting
Trial results get compressed into headlines. Here is what gets lost, and how to read the next one.
FDA Approved Orzeyful, Replacing What Narcolepsy Type 1 Patients Lack
The August 5, 2026 approval of oveporexton brings the first orexin receptor agonist to market — wakefulness restored, not stimulated. What patients should ask.
Latest
FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL
The July 15, 2026 approval of enlicitide turns an injection class costing thousands per year into a daily pill. Trial numbers, coverage questions, what's next.
Medicaid Expansion: Who Qualifies at 138 Percent of the Poverty Line — and Who Falls in the Gap
Forty states and the District of Columbia have expanded Medicaid to most adults under 138 percent of poverty; in the remaining holdout states, adults too poor for subsidies still have no option.
FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs
The June 17, 2026 approval of tebipenem lets some kidney-infection patients leave the infusion chair for a pill — if stewardship rules hold the line on use.
MedPAC's June Report Lands With Medicare Advantage at 55 Percent
The June 15, 2026 report to Congress arrived as MA enrollment passed 55 percent of beneficiaries and oversight findings piled up. What its recommendations could change.